Avalon GloboCare Corp. – NASDAQ:ALBT
Avalon GloboCare Corp. stock price today
Avalon GloboCare Corp. stock price monthly change
Avalon GloboCare Corp. stock price quarterly change
Avalon GloboCare Corp. stock price yearly change
Avalon GloboCare Corp. key metrics
Market Cap | 3.83M |
Enterprise value | 21.04M |
P/E | -1.71 |
EV/Sales | 16.96 |
EV/EBITDA | -2.66 |
Price/Sales | 16.43 |
Price/Book | 4.45 |
PEG ratio | -0.05 |
EPS | -1.41 |
Revenue | 1.27M |
EBITDA | -4.49M |
Income | -14.95M |
Revenue Q/Q | 6.22% |
Revenue Y/Y | 6.11% |
Profit margin | -955.4% |
Oper. margin | -711.47% |
Gross margin | 26.32% |
EBIT margin | -711.47% |
EBITDA margin | -353.14% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAvalon GloboCare Corp. stock price history
Avalon GloboCare Corp. stock forecast
Avalon GloboCare Corp. financial statements
| Jun 2023 | 306.90K | -2.54M | -828.7% |
|---|---|---|---|
| Sep 2023 | 331.29K | -1.48M | -448.27% |
| Dec 2023 | 321.32K | -9.55M | -2973.7% |
| Mar 2024 | 314.58K | -1.36M | -434.7% |
| Jun 2023 | 30570584 | 12.41M | 40.62% |
|---|---|---|---|
| Sep 2023 | 29967181 | 13.14M | 43.86% |
| Dec 2023 | 20582536 | 13.21M | 64.2% |
| Mar 2024 | 20333236 | 14.27M | 70.23% |
| Jun 2023 | -2.52M | -2.01K | 2.29M |
|---|---|---|---|
| Sep 2023 | -1.34M | 30 | 1.04M |
| Dec 2023 | -748.03K | 468.76K | 225.00K |
| Mar 2024 | -915.70K | 1.21M | -273.7K |
Avalon GloboCare Corp. alternative data
| Aug 2023 | 5 |
|---|---|
| Sep 2023 | 5 |
| Oct 2023 | 5 |
| Nov 2023 | 5 |
| Dec 2023 | 5 |
| Jan 2024 | 5 |
| Feb 2024 | 5 |
| Mar 2024 | 5 |
| Apr 2024 | 5 |
| May 2024 | 4 |
| Jun 2024 | 4 |
| Jul 2024 | 4 |
Avalon GloboCare Corp. other data
| Period | Buy | Sel |
|---|---|---|
| Jun 2019 | 36000 | 0 |
| Apr 2020 | 645161 | 0 |
-
What's the price of Avalon GloboCare Corp. stock today?
One share of Avalon GloboCare Corp. stock can currently be purchased for approximately $2.04.
-
When is Avalon GloboCare Corp.'s next earnings date?
Unfortunately, Avalon GloboCare Corp.'s (ALBT) next earnings date is currently unknown.
-
Does Avalon GloboCare Corp. pay dividends?
No, Avalon GloboCare Corp. does not pay dividends.
-
How much money does Avalon GloboCare Corp. make?
Avalon GloboCare Corp. has a market capitalization of 3.83M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 4.45% to 1.26M US dollars.
-
What is Avalon GloboCare Corp.'s stock symbol?
Avalon GloboCare Corp. is traded on the NASDAQ under the ticker symbol "ALBT".
-
What is Avalon GloboCare Corp.'s primary industry?
Company operates in the Real Estate sector and Real Estate - Services industry.
-
How do i buy shares of Avalon GloboCare Corp.?
Shares of Avalon GloboCare Corp. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Avalon GloboCare Corp. have?
As Jul 2024, Avalon GloboCare Corp. employs 4 workers, which is 20% less then previous quarter.
-
When Avalon GloboCare Corp. went public?
Avalon GloboCare Corp. is publicly traded company for more then 7 years since IPO on 27 Mar 2018.
-
What is Avalon GloboCare Corp.'s official website?
The official website for Avalon GloboCare Corp. is avalon-globocare.com.
-
Where are Avalon GloboCare Corp.'s headquarters?
Avalon GloboCare Corp. is headquartered at 4400 Route 9 South, Freehold, NJ.
-
How can i contact Avalon GloboCare Corp.?
Avalon GloboCare Corp.'s mailing address is 4400 Route 9 South, Freehold, NJ and company can be reached via phone at +7 327804400.
Avalon GloboCare Corp. company profile:
Avalon GloboCare Corp.
avalon-globocare.comNASDAQ
4
Real Estate - Services
Real Estate
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.
Freehold, NJ 07728
CIK: 0001630212
ISIN: US05344R2031
CUSIP: 05344R203
